

## References for tables 1-7

1. Collins SR, Rasmussen PW, Doty MM, et al. The rise in health care coverage and affordability since health reform took effect: findings from the Commonwealth Fund Biennial Health Insurance Survey, 2014. *Issue Brief (Commonw Fund)* 2015;2:1-16. [published Online First: 2015/03/27]
2. Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. *BMJ Open* 2017;7(1) doi: 10.1136/bmjopen-2016-014287
3. Jacobs DB, Sommers BD. Using Drugs to Discriminate — Adverse Selection in the Insurance Marketplace. *N Engl J Med* 2015;372(5):399-402. doi: doi:10.1056/NEJMp1411376
4. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood* 2013;121(22):4439-42. doi: 10.1182/blood-2013-03-490003 [published Online First: 2013/04/27]
5. Kantarjian H. The arrival of generic imatinib into the U.S. market: an educational event. *The ASCO Post* 2016. <http://www.ascopost.com...> (accessed May 25,).
6. Doshi JA, Li P, Huo H, et al. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. *Am J Manag Care* 2016;22(4 Suppl):s78-86. [published Online First: 2016/06/09]
7. Pollack A. Drug goes from \$13.50 a tablet to \$750, overnight. *New York Times* 2015 September 20. <http://www.nytimes.com...> (accessed September 18, 2016).
8. Parker-Pope T, Peachman RR. EpiPen price rise sparks concern for allergy sufferers. *The New York Times* 2016 August 22. <http://well.blogs.nytimes.com...> (accessed September 18, 2016).
9. Alpern JD, Stauffer WM, Kesselheim AS. High-Cost Generic Drugs — Implications for Patients and Policymakers. *N Engl J Med* 2014;371(20):1859-62. doi: doi:10.1056/NEJMp1408376
10. Barua S, Greenwald R, Grebely J, et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med* 2015;163(3):215-23. doi: 10.7326/m15-0406 [published Online First: 2015/06/30]
11. Exceptional Access Program (EAP). Toronto: Ontario Ministry of Health and Long-Term Care 2017. <http://www.health.gov.on.ca...>
12. Patented Medicine Prices Review Board. Annual report 2016. Ottawa: PMPRB 2017.
13. Lexchin J. How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study. *Healthcare Policy* 2016;12(2):65-75. [published Online First: 2016/12/30]
14. Lanthier M, Miller KL, Nardinelli C, et al. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. *Health Aff (Millwood)* 2013;32(8):1433-9. doi: 10.1377/hlthaff.2012.0541 [published Online First: 2013/08/07]
15. Mailankody S, Prasad V. Five years of cancer drug approvals: Innovation, efficacy, and costs. *JAMA Oncology* 2015;1(4):539-40. doi: 10.1001/jamaoncol.2015.0373
16. Kumar H, Fojo T, Mailankody S. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. *JAMA Oncology* 2016;2:1238-40.
17. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of us food and drug administration approvals. *JAMA Intern Med* 2015;175(12):1992-94. doi: 10.1001/jamainternmed.2015.5868

18. Rupp T, Zuckerman D. Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints. *JAMA Intern Med* 2016 doi: 10.1001/jamainternmed.2016.7761
19. Vitry AI, Shin NH, Vitre P. Assessment of the therapeutic value of new medicines marketed in Australia. *J Pharm Policy Pract* 2013;6:2. doi: 10.1186/2052-3211-6-2 [published Online First: 2013/01/01]
20. Ward DJ, Slade A, Genus T, et al. How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012. *BMJ Open* 2014;4(10):e006235. doi: 10.1136/bmjopen-2014-006235 [published Online First: 2014/10/26]
21. Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. *BMJ* 2017;359 doi: 10.1136/bmj.j4530
22. Joppi R, Bertele V, Garattini S. Disappointing biotech. *BMJ* 2005;331(7521):895-7. doi: 10.1136/bmj.331.7521.895 [published Online First: 2005/10/15]
23. Motola D, De Ponti F, Poluzzi E, et al. An update on the first decade of the European centralized procedure: how many innovative drugs? *Br J Clin Pharmacol* 2006;62(5):610-6. doi: 10.1111/j.1365-2125.2006.02700.x [published Online First: 2006/06/27]
24. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. *JAMA* 1999;282(18):1752-9. [published Online First: 1999/11/24]
25. Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: A cautionary tale. *JAMA Intern Med* 2013;173(8):611-12. doi: 10.1001/jamainternmed.2013.3037
26. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 2008;358(3):252-60. doi: 10.1056/NEJMsa065779
27. Hwang TJ, Carpenter D, Lauffenburger JC, et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. *JAMA Intern Med* 2016;176(12):1826-33. doi: 10.1001/jamainternmed.2016.6008 [published Online First: 2016/10/11]
28. Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. *Cochrane Database Syst Rev* 2017;2:Mr000033. doi: 10.1002/14651858.MR000033.pub3 [published Online First: 2017/02/17]
29. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. *N Engl J Med* 2008;358(13):1354-61. doi: 10.1056/NEJMsa0706341 [published Online First: 2008/03/28]
30. Frank C, Himmelstein DU, Woolhandler S, et al. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. *Health Aff (Millwood)* 2014;33(8):1453-59. doi: 10.1377/hlthaff.2014.0122
31. Olson MK. The risk we bear: the effects of review speed and industry user fees on new drug safety. *J Health Econ* 2008;27(2):175-200. doi: 10.1016/j.jhealeco.2007.10.007 [published Online First: 2008/01/22]
32. Fralick M, Kesselheim AS. FDA approval of desmopressin for nocturia. *JAMA* 2017 doi: 10.1001/jama.2017.4316
33. Maund E, Schow Guski L, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. *Can Med Assoc J* 2016 doi: 10.1503/cmaj.151104

34. Lexchin J. New drugs and safety: What happened to new active substances approved in Canada between 1995 and 2010? *Arch Intern Med* 2012;172(21):1680-81. doi: 10.1001/archinternmed.2012.4444
35. Lexchin J. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. *Br J Clin Pharmacol* 2015;79(5):847-59. doi: 10.1111/bcp.12552 [published Online First: 2014/11/14]
36. Mostaghim SR, Gagne JJ, Kesselheim AS. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study. *BMJ* 2017;358 doi: 10.1136/bmj.j3837
37. Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. *JAMA Intern Med* 2014;174(1):90-5. doi: 10.1001/jamainternmed.2013.11813 [published Online First: 2013/10/30]
38. Fain K, Daubresse M, Alexander G. The food and drug administration amendments act and postmarketing commitments. *JAMA* 2013;310(2):202-04. doi: 10.1001/jama.2013.7900
39. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. *N Engl J Med* 2004;351(17):1707-9. doi: 10.1056/NEJMp048286
40. Korenstein D, Keyhani S, Mendelson A, et al. Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. *PLoS One* 2011;6(8):e23336. doi: 10.1371/journal.pone.0023336
41. Othman N, Vitry A, Roughead EE. Quality of pharmaceutical advertisements in medical journals: a systematic review. *PLoS One* 2009;4(7):e6350. doi: 10.1371/journal.pone.0006350
42. Almashat S, Wolfe S, Carome M. Twenty-Five Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2015. 2016. <https://www.citizen.org...> (accessed December 7, 2017).
43. Gagnon M-A, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. *PLoS Med* 2008;5(1):e1. doi: 10.1371/journal.pmed.0050001
44. Kornfield R, Donohue J, Berndt ER, et al. Promotion of Prescription Drugs to Consumers and Providers, 2001–2010. *PLoS One* 2013;8(3):e55504. doi: 10.1371/journal.pone.0055504
45. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. *PLoS Med* 2010;7(10):e1000352. doi: 10.1371/journal.pmed.1000352
46. Office of the Actuary in the Centers for Medicare & Medicaid Services. National Health Expenditure Estimates, 2016-2025. <https://www.cms.gov...> (accessed November 15, 2017).
47. Services: DoHaH, Office of the Assistant Secretary for Planning and Evaluation. Observations on Trends in Prescription Drug Spending 2016 [Available from: <https://aspe.hhs.gov...> accessed November 6, 2017].
48. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: Origins and prospects for reform. *JAMA* 2016;316(8):858-71. doi: 10.1001/jama.2016.11237
49. IMS Health. Medicines Use and Spending in the U.S.: A Review of 2016 and Outlook to 2021. 2017 [Available from: <https://www.iqvia.com...>].
50. Squires DA. Explaining high health care spending in the United States: an international comparison of supply, utilization, prices, and quality. *Commonwealth Fund Issue Brief* 2012;10:1-14.

51. Gagnon M-AG, Wolfe S. Mirror, Mirror on the Wall. 2015. <https://www.citizen.org...> (accessed December 6, 2016).
52. Kanavos P, Ferrario A, Vandoros S, et al. Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs. *Health Aff (Millwood)* 2013;32(4):753-61. doi: 10.1377/hlthaff.2012.0920
53. Congressional Budget Office. Prices for Brand-Name Drugs Under Selected Federal Programs. 2005. <https://www.cbo.gov...> (accessed December 6, 2016).
54. Frakt AB, Pizer SD, Feldman R. Should Medicare adopt the Veterans Health Administration formulary? *Health Econ* 2012;21(5):485-95. doi: 10.1002/hec.1733
55. Baker D. The benefits and savings from publicly funded clinical trials of prescription drugs. *Int J Health Serv* 2008;38(4):731-50. [published Online First: 2008/12/17]
56. Congressional Budget Office. Federal Subsidies for Health Insurance Coverage for People Under Age 65: 2017 to 2027. 2017. <https://www.cbo.gov...> (accessed November 15, 2017).
57. Mulcahy AW, Eibner C, Finegold K. Gaining Coverage Through Medicaid Or Private Insurance Increased Prescription Use And Lowered Out-Of-Pocket Spending. *Health Aff (Millwood)* 2016 doi: 10.1377/hlthaff.2016.0091
58. Choudhry NK, Avorn J, Glynn RJ, et al. Full Coverage for Preventive Medications after Myocardial Infarction. *N Engl J Med* 2011;365(22):2088-97. doi: doi:10.1056/NEJMsa1107913
59. Research and development expenditure of total U.S. pharmaceutical industry from 1995 to 2015 (in billion U.S. dollars) [Available from: <https://www.statista.com...> accessed February 28, 2017].
60. Chakravarthy R, Cotter K, DiMasi J, et al. Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy. *Therapeutic Innovation & Regulatory Science* 2016 doi: 10.1177/2168479016648730
61. US Department of Health and Human Services. HHS FY 2017 Budget in Brief - FDA: US Department of Health and Human Services; [Available from: <https://www.hhs.gov...> accessed February 28, 2017].
62. Food and Drug Administration. Crosscutting Information [Available from: <https://www.fda.gov...> accessed February 28, 2017].